Boston Scientific 1Q Earnings Climb After Acquisitions, Product Launches
26 Abril 2023 - 6:54AM
Noticias Dow Jones
By Dia Gill
Boston Scientific Corp. said earnings soared in the first
quarter as it completed two acquisitions and made significant
headway on several products in development.
The Marlborough, Mass.-based biomedical engineering company said
net income rose to $300 million, or 21 cents per share, for the
quarter ended March 31, up from $97 million, or 7 cents per share,
in the year-ago period.
Sales rose to $3.39 billion, up from $3.03 billion in the
year-ago period. Analysts surveyed by FactSet had expected sales of
$3.16 billion, and the company had projected a 3% to 5% increase in
sales in its own guidance.
Two business segments, MedSurg and Cardiovascular, saw growth of
11% and 12.7%, respectively.
During the quarter, Boston Scientific received U.S. Food and
Drug Administration clearance to launch its LithoVue Elite
Single-Use Digital Flexible Ureteroscope System. The company also
completed the acquisitions of Apollo Endosurgery Inc. and a
majority stake investment in Acotec, a Chinese medical technology
company.
The LithoVue Elite Single-Use Digital Flexible Ureteroscope
System assists urologists in monitoring intrarenal pressure in
real-time during ureteroscopy procedures. Its launch was joined by
positive trial results and progress in developing several other
medical technologies.
Write to Dia Gill at dia.gill@wsj.com
(END) Dow Jones Newswires
April 26, 2023 07:39 ET (11:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Boston Scientific (NYSE:BSX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Boston Scientific (NYSE:BSX)
Gráfica de Acción Histórica
De May 2023 a May 2024
